[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Eric Adler, Chief Medical Officer of Lexeo Therapeutics, Inc. (LXEO), reported a transaction dated 08/18/2025 on Form 4 showing a sale of 608 shares of Common Stock at $4.668 per share. The filing explains the sale was to cover tax obligations on the release of restricted stock units (RSUs). Following the reported transaction, Adler beneficially owns 67,073 shares, which the filing notes includes 60,546 RSUs. The form was executed by an attorney-in-fact on 08/20/2025. The filing discloses the insider relationship and provides the required Section 16 reporting information.

Positive

• Timely Section 16 disclosure of the insider transaction ensuring regulatory transparency
• Sale explicitly identified as tax-withholding related to RSU release, clarifying the reason for disposition

Negative

• Insider disposition of 608 shares at $4.668 reduces direct shareholdings
• Large portion of holdings in RSUs (60,546 of 67,073 shares), indicating concentrated equity exposure tied to compensation

Insights

Securities Analyst

TL;DR: Officer sold a small number of shares to satisfy tax withholding on RSU vesting; ownership remains concentrated in RSUs.

The reported sale of 608 shares at $4.668 is documented as a tax-withholding transaction tied to RSU release, not an open-market divestiture for investment reasons. The remaining beneficial position of 67,073 shares, including 60,546 RSUs, indicates most current exposure is via unvested/vested equity awards rather than free-float shares. This Form 4 is a routine disclosure under Section 16 and provides transparency on insider equity mechanics; it does not by itself reveal changes to company strategy, operations, or governance.

Corporate Governance Expert

TL;DR: Filing is a standard compliance disclosure showing a tax-related sale; no governance red flags disclosed.

The submission identifies the reporting person and role, the transaction date, and gives a clear explanation that the sale was to cover tax obligations on RSU release. Execution by an attorney-in-fact is properly noted and signed. There are no indications of unusual trading patterns, related-party transactions, or departures from standard Section 16 reporting practices in the text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adler Eric

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S(1)		608	D	$4.668	67,073(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. Includes 60,546 RSUs.

	/s/ Youjin Choi, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Eric Adler report on the Form 4 for LXEO?

The Form 4 reports a sale of 608 shares of Lexeo Therapeutics common stock on 08/18/2025 at $4.668 per share to cover tax obligations from RSU release.

How many shares does Eric Adler beneficially own after the transaction?

Following the reported sale, Adler beneficially owns 67,073 shares, which includes 60,546 RSUs.

Was the sale an open-market trade or for another purpose?

The filing explains the sale was made to cover tax obligations on the release of restricted stock units, not described as an investment-motivated market sale.

When was the Form 4 signed and by whom?

The Form 4 was signed by Youjin Choi, Attorney-in-Fact on 08/20/2025.

What is Eric Adler's role at Lexeo Therapeutics?

The filing identifies Eric Adler as the company's Chief Medical Officer.